RMNI vs. OPRX, PAYS, PRTH, ZFOX, DHX, STCN, SCOR, EGIO, MCHX, and EEX
Should you be buying Rimini Street stock or one of its competitors? The main competitors of Rimini Street include OptimizeRx (OPRX), Paysign (PAYS), Priority Technology (PRTH), ZeroFox (ZFOX), DHI Group (DHX), Steel Connect (STCN), comScore (SCOR), Edgio (EGIO), Marchex (MCHX), and Emerald (EEX). These companies are all part of the "business services, not elsewhere classified" industry.
OptimizeRx (NASDAQ:OPRX) and Rimini Street (NASDAQ:RMNI) are both small-cap computer and technology companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations, valuation and community ranking.
In the previous week, OptimizeRx had 13 more articles in the media than Rimini Street. MarketBeat recorded 15 mentions for OptimizeRx and 2 mentions for Rimini Street. OptimizeRx's average media sentiment score of 0.89 beat Rimini Street's score of 0.11 indicating that Rimini Street is being referred to more favorably in the news media.
Rimini Street received 9 more outperform votes than OptimizeRx when rated by MarketBeat users. Likewise, 63.49% of users gave Rimini Street an outperform vote while only 63.16% of users gave OptimizeRx an outperform vote.
OptimizeRx has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500. Comparatively, Rimini Street has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500.
OptimizeRx presently has a consensus target price of $16.00, indicating a potential upside of 26.08%. Rimini Street has a consensus target price of $4.50, indicating a potential upside of 85.95%. Given OptimizeRx's higher possible upside, analysts plainly believe Rimini Street is more favorable than OptimizeRx.
76.5% of OptimizeRx shares are held by institutional investors. Comparatively, 73.8% of Rimini Street shares are held by institutional investors. 4.4% of OptimizeRx shares are held by company insiders. Comparatively, 41.3% of Rimini Street shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Rimini Street has higher revenue and earnings than OptimizeRx. OptimizeRx is trading at a lower price-to-earnings ratio than Rimini Street, indicating that it is currently the more affordable of the two stocks.
Rimini Street has a net margin of 5.02% compared to Rimini Street's net margin of -23.10%. Rimini Street's return on equity of -6.96% beat OptimizeRx's return on equity.
Summary
Rimini Street beats OptimizeRx on 12 of the 18 factors compared between the two stocks.
Get Rimini Street News Delivered to You Automatically
Sign up to receive the latest news and ratings for RMNI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RMNI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rimini Street Competitors List
Related Companies and Tools
